Latest News and Press Releases

Ordinær generalforsamling i ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) finder sted mandag den 16. marts 2026 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede...

The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag meddelt, at Henriette Mersebach fratræder som Executive Vice President, Research and Development, og som medlem af direktionen med virkning fra 23....

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management,...

ALK’s (ALKB:DC / Nasdaq Copenhagen: ALK B) full-year results came in at the top end of the latest outlook, supported by solid performance in Q4 and continued commercial momentum. ALK expects sustained...

ALK (ALKB:DC / OMX: ALK B) offentliggør sin årsrapport for 2025 om morgenen fredag den 20. februar 2026. ALK afholder senere samme dag kl. 13.30 (CET) en præsentation for investorer og analytikere,...

ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts...

Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at Det Europæiske Lægemiddelagenturs komite for godkendelse af medicin til mennesker (Committee for Medicinal Products for Human Use,...

Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion...

ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44th Annual J.P. Morgan Healthcare Conference in...